Torrent Pharmaceuticals announced that it will buy more than 120 brands from Unichem Laboratories in India and Nepal, and its manufacturing plant at Sikkim.
The $558 million transaction will strengthen Torrent’s position in cardiology, diabetes, gastro-intestinals and central nervous systems therapies, as well as add Torrent to the list of top pharma firms in the Indian Pharma market.
Unichem will continue to focus on international business comprising of manufacturing, selling and marketing of fixed dosage formulation and API. It will also continue to build a sustainable revenue stream by investing in R&D.
Read the press release